I’m disappointed and you should be too. Today, the Food & Drug Administration announced the approval of flibanserin, a proposed treatment for “hypoactive sexual desire disorder” in women. Since its founding, the National Women’s Health Network has ensured that the voices of women consumers are heard and respected. Today, clever marketing trumped decades worth of consumer protections that the Network has worked hard to secure and maintain.
Learn about 5 common myths surrounding sex drugs like Addyi and Viagra as well as the FDA’s approach to this issue.
Food and Drug Administration Scientific Workshop on Female Sexual Interest/Arousal Disorder